Company profile

Grit Biotechnology

Privately held: no public share price (Private cell-therapy company; CNY 600M raised Oct 2025 and a $60M Series B in 2023, no IPO found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.marketscreener.com/news/grit-biotechnology-announced-that-it-has-received-cny-600-million-in-funding-from-beijing-shunxi-ven-ce7d5adedf8ff22c]) · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
GT737
Phase 1
CD33 / CD70
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.